Mirae Asset Global Investments Co. Ltd. Purchases 1,002 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Mirae Asset Global Investments Co. Ltd. raised its stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 38.4% during the third quarter, Holdings Channel reports. The fund owned 3,611 shares of the company’s stock after buying an additional 1,002 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Day One Biopharmaceuticals were worth $51,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of DAWN. Janus Henderson Group PLC grew its position in Day One Biopharmaceuticals by 19.8% during the first quarter. Janus Henderson Group PLC now owns 2,032,384 shares of the company’s stock worth $33,575,000 after buying an additional 336,281 shares in the last quarter. AQR Capital Management LLC lifted its stake in Day One Biopharmaceuticals by 517.0% during the second quarter. AQR Capital Management LLC now owns 113,020 shares of the company’s stock worth $1,557,000 after purchasing an additional 94,703 shares during the last quarter. ProShare Advisors LLC boosted its holdings in Day One Biopharmaceuticals by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 17,379 shares of the company’s stock valued at $287,000 after acquiring an additional 1,447 shares during the period. Deerfield Management Company L.P. Series C boosted its holdings in Day One Biopharmaceuticals by 65.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 2,923,137 shares of the company’s stock valued at $40,281,000 after acquiring an additional 1,157,825 shares during the period. Finally, Essex Investment Management Co. LLC purchased a new stake in Day One Biopharmaceuticals during the 3rd quarter valued at about $2,566,000. 87.95% of the stock is currently owned by hedge funds and other institutional investors.

Day One Biopharmaceuticals Stock Performance

DAWN opened at $15.15 on Wednesday. The stock has a market cap of $1.53 billion, a price-to-earnings ratio of -14.71 and a beta of -1.51. The stock’s 50 day moving average price is $14.20 and its 200-day moving average price is $14.38. Day One Biopharmaceuticals, Inc. has a one year low of $10.90 and a one year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.58. The company had revenue of $93.76 million for the quarter, compared to analysts’ expectations of $15.05 million. During the same quarter in the prior year, the company earned ($0.54) EPS. As a group, analysts predict that Day One Biopharmaceuticals, Inc. will post -1.22 earnings per share for the current fiscal year.

Insider Transactions at Day One Biopharmaceuticals

In other news, CFO Charles N. York II sold 2,633 shares of the company’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $14.00, for a total transaction of $36,862.00. Following the transaction, the chief financial officer now directly owns 232,485 shares of the company’s stock, valued at approximately $3,254,790. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CFO Charles N. York II sold 2,633 shares of the company’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $14.00, for a total transaction of $36,862.00. Following the transaction, the chief financial officer now directly owns 232,485 shares of the company’s stock, valued at approximately $3,254,790. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Samuel C. Blackman sold 2,232 shares of the company’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $14.00, for a total value of $31,248.00. Following the transaction, the insider now directly owns 1,127,535 shares in the company, valued at approximately $15,785,490. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 49,248 shares of company stock valued at $697,082. Corporate insiders own 8.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Wedbush reiterated an “outperform” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, July 25th. Needham & Company LLC reaffirmed a “buy” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. TD Cowen raised Day One Biopharmaceuticals to a “strong-buy” rating in a research report on Monday. JPMorgan Chase & Co. reduced their target price on Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $35.71.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.